Eye drop preparation containing combined bacteriostatic agent and eye drop preparation product comprising same
A technology of eye drops and bacteriostatic agents, applied in the field of medicine, can solve the problems of insufficient bacteriostatic effect and easy degradation of bacteriostatic agents, and achieve the effect of preventing the growth and reproduction of microorganisms, improving the bacteriostatic effect and good compatibility.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach
[0063] The invention and its advantages will be described in detail below by means of exemplary embodiments. The description of the exemplary embodiments is illustrative only, and in no way serves as any limitation of the disclosure, its application or uses. The present disclosure can be implemented in many different forms and is not limited to the embodiments described here. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art. It should be noted that unless otherwise stated, the relative arrangement of components and steps, material composition, numerical expressions and numerical values, etc. set forth in these embodiments should be interpreted as merely exemplary and not limiting.
[0064] Materials and instruments used:
[0065] Pearl liquid: the peptide content is about 3.28mg / mL, made in the laboratory;
[0066] Borneol: commercially available from A...
Embodiment 12
[0162] Embodiment 12 uses high-density polyethylene packaging material, after accelerated investigation 6 months, paraben bacteriostatic agent and amino acid content all reduce in varying degrees, compare with the content at 0 o'clock, the methyl paraben content drops to 88.5%, propyl p-hydroxybenzoate content dropped to 85.3%, amino acid content dropped to 89.9%, borneol content dropped to 76.3%, these indicators still meet relevant quality standards.
Embodiment 13
[0163] Embodiment 13 uses low-density polyethylene packaging materials, and after accelerated inspection for 6 months, the content of methyl p-hydroxybenzoate drops to 93.8%, the content of propyl p-hydroxybenzoate drops to 94.1%, the content of amino acids drops to 89.5%, and the content of borneol It was still higher than 0.2mg / mL after 3 months of accelerated investigation, but it was lower than the requirement that the borneol content in the quality standard was not less than 0.2mg / mL after 6 months of accelerated investigation, and dropped significantly to only 0.2 mg / mL of borneol content at 0 o'clock. About 27.5%. Without wishing to be bound by theory, it is speculated here that borneol is volatile and easily volatilizes through low-density polyethylene, resulting in a reduction in borneol content. Therefore, the packaging material for pearl eye drops of the present invention is not preferably used for long-term use of low-density Made of polyethylene.
PUM
| Property | Measurement | Unit |
|---|---|---|
| Wavelength | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More